Medicare Part B International Price Index Could Result In 25% R&D Cuts – Study

Reductions in research and development spending will be much greater than the 1% average often quoted by HHS, consultant tells the Biotechnology Innovation Organization annual convention.

pills #259294352

The proposed US International Pricing Index model for Medicare Part B drugs will lead to much larger reductions in research and development spending than the 1% average often quoted by HHS, according to Vital Transformation managing partner Duane Schulthess.

HHS released an advance notice of proposed rulemaking on the IPI in October 2018. The notice previewed plans to test...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Medicare

More from Government Payers